Increased Healthcare Resource Use and Costs After Discontinuation of Liraglutide in Patients with Type 2 Diabetes from a Commercial- and Medicaid-Insured Claims Database

por Uzoigwe, Chioma, Noone, Josh, Liang, Yuanjie, Ali, Sarah Naz, Gamble, Cory
Publicado 2022

Insights into the early use of oral semaglutide in routine clinical practice: The IGNITE study

por Aroda, Vanita R., Faurby, Mads, Lophaven, Søren, Noone, Josh, Wolden, Michael Lyng, Lingvay, Ildiko
Publicado 2021

Once-weekly glucagon-like peptide-1 receptor agonists vs dipeptidyl peptidase-4 inhibitors: cardiovascular effects in people with diabetes and cardiovascular disease

por Tan, Xi, Liang, Yuanjie, Rajpura, Jigar R., Yedigarova, Larisa, Noone, Josh, Xie, Lin, Inzucchi, Silvio, de Havenon, Adam
Publicado 2023

Early experiences of nusinersen for the treatment of spinal muscular atrophy: Results from a large survey of patients and caregivers

por Chen, Er, Dixon, Stacy, Naik, Rupali, Noone, Josh M., Buchenberger, J. Daniel, Whitmire, Sarah M., Mills, Rosalina, Arnold, William
Publicado 2020

Real-World Hemoglobin A1c Changes, Prescribing Provider Types, and Medication Dose Among Patients with Type 2 Diabetes Mellitus Initiating Treatment with Oral Semaglutide

por Frazer, Monica, Swift, Caroline, Gronroos, Noelle N., Sargent, Andrew, Leszko, Michael, Buysman, Erin, Alvarez, Sara, Dunn, Tyler J., Noone, Josh, Guevarra, Mico
Publicado 2023